Trial Profile
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Sep 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Erlotinib; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 19 Nov 2016 Results assessing Trametinib Plus Docetaxel or Pemetrexed in patients with non-small cell lung cancer, published in the Journal of Thoracic Oncology
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2013 Planned end date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.